Court denies Novartis injunction against Teva

JERUSALEM, Israel Teva Pharmaceutical Industries announced Wednesday that the U.S. District Court for the District of New Jersey denied a motion filed by Novartis for a preliminary injunction related to Teva's famciclovir tablets, the generic version of Novartis' Famvir.

The Food and Drug Administration already has approved Teva's abbreviated new drug application for famciclovir tablets. As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.

Famvir had U.S. annual sales of approximately $200 million for the twelve months ended June 30, according to IMS sales data.